Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Ro­te-Hand-Brief: Re­mi­ca­de, Fli­xa­bi, In­flec­tra, Rem­si­ma und Zess­ly (In­fli­xi­mab)

Anwendung von Lebendimpfstoffen bei Säuglingen, die in utero oder über das Stillen exponiert waren

Rote-Hand-Brief: Remicade, Flixabi, Inflectra, Remsima und Zessly - Infliximab (07.03.2022)

Aktualisiert: 07.03.2022